MOUNTAIN VIEW, Calif. — Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company developing precision medicines for neuropsychiatric disorders, has appointed Raymond Sanchez, M.D., to its Board of Directors, effective August 12, 2025.
“We are delighted to welcome Ray to our Board of Directors as we continue advancing multiple clinical-stage precision psychiatry programs,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. “Ray brings an impressive track record in guiding the successful development of numerous CNS therapies, and his strategic insights will be instrumental as we prepare to initiate our potentially pivotal, Phase 2b trial of ALTO-207. Ray is a tremendous addition to our board, and we believe his dedication to improving patient outcomes through innovation in psychiatry bring important contributions to our mission.”
Dr. Sanchez said, “As a psychiatrist by training, I’ve witnessed firsthand the lack of innovation in the field, even as it remains one of the most urgent areas of unmet medical need. I’m thrilled to join Alto at such an exciting time as the company aims to redefine the standard of care by moving beyond the outdated trial-and-error approach that has long dominated CNS drug development and clinical practice. With a robust late-stage pipeline and a strategic vision rooted in biology-driven precision medicine, I look forward to supporting Alto’s mission to deliver novel therapeutic solutions to the patients who need them most.”
Sanchez currently serves as a senior advisor at Bain Capital Life Sciences and sits on the board of directors for Rapport Therapeutics, Inc. (Nasdaq: RAPP) and several privately held biotechnology companies. He previously served as chief medical officer of Cerevel Therapeutics Holdings, Inc. from 2019 until its 2024 acquisition by AbbVie Inc., and held senior roles at Otsuka Pharmaceutical Development & Commercialization, Inc., including senior vice president of global clinical development. He also served as chief medical officer of Avanir Pharmaceuticals, Inc.
A trained psychiatrist, Sanchez completed his residency at the Yale School of Medicine, where he was chief resident, fellow, and instructor. He has held leadership positions in industry organizations, including serving as executive co-chair of the International Society for CNS Drug Development from 2017 to 2022, and has contributed to various academic and charitable organizations. Sanchez earned his bachelor’s degree in psychology and his medical degree from Northwestern University.
